Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Rituximab Associated Necrosis: A Case Report Publisher Pubmed



Ashtari F1 ; Hakamifard A2 ; Hariri A3 ; Gholipourshahraki T4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Isfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Infectious Diseases, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Multiple Sclerosis and Related Disorders Published:2020


Abstract

Background: Rituximab is a B-cell-depleting unconjugated monoclonal IgG1 antibody that targets the transmembrane protein CD20. This article reports on a case with the rare complication known as Rituximab-associated mucosal necrosis. Case presentation: The present case report addresses, for the first time, a patient affected by Devic's syndrome presenting with oral manifestations of palatal necrosis after rituximab treatment. Conclusion: The present case raises the possibility of anti-CD20 antibody contributing to the development of palatal mucosal necrosis in some patients. Given the increasing administration of rituximab as a result of its efficacy against several diseases, a report on the potential iatrogenic effects of this drug is essential. © 2019 Elsevier B.V.